Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer

Anne-Laure Couderc, Laetitia Ninove, Emilie Nouguerède, Dominique Rey, Marina Rebroin, Aurélie Daumas, Pascale Tomasini, Laurent Greillier, Sebastien Salas, Florence Duffaud, Laetitia Dahan, Muriel Duluc, Marie-Eve Garcia, Johan Pluvy, Solène Chaléat, Laure Farnault, Geoffroy Venton, Toscane Fourié, Elif Nurtop, Xavier de Lamballerie, Patrick Villani, Remi Charrel, Florian Correard, Anne-Laure Couderc, Laetitia Ninove, Emilie Nouguerède, Dominique Rey, Marina Rebroin, Aurélie Daumas, Pascale Tomasini, Laurent Greillier, Sebastien Salas, Florence Duffaud, Laetitia Dahan, Muriel Duluc, Marie-Eve Garcia, Johan Pluvy, Solène Chaléat, Laure Farnault, Geoffroy Venton, Toscane Fourié, Elif Nurtop, Xavier de Lamballerie, Patrick Villani, Remi Charrel, Florian Correard

Abstract

Purpose: The COVID-19 vaccination campaign began in December 2020, in France, and primarily targeted the oldest people. Our study aimed to determine the level of acceptance of vaccination in a population of older patients with cancer.

Methods: From January 2021, we offered vaccination with the BNT162b2 COVID-19 vaccine to all patients 70 years and older referred to our geriatric oncology center in Marseille University Hospital (AP-HM) for geriatric assessment before initiation of an oncological treatment. Objectives were to evaluate acceptance rate of COVID-19 vaccination and to assess vaccine safety, reactogenicity, and efficacy two months after the first dose.

Results: Between January 18, 2021 and May 7, 2021, 150 older patients with cancer were offered vaccination after a geriatric assessment. The majority were men (61.3%), with a mean age of 81 years. The two most frequent primary tumors were digestive (29.4%) and thoracic (18%). The vaccine acceptance rate was 82.6% and the complete vaccination rate (2 doses) reached 75.3%. Among the vaccinated patients, 15.9% reported mild side effects after the first dose and 23.4% after the second dose, mostly arm pain and fatigue. COVID-19 cases were observed in 5.1% of vaccinated patients compared with 16.7% in unvaccinated patients. Of the 22 vaccinated patients who agreed to have their serum tested, 15 had antibodies against the spike protein at day 21 after the first dose.

Conclusion: Our study showed a high acceptance rate of COVID-19 vaccination, with good tolerance in this frail population. These results highlight the benefits of organizing vaccination campaigns at the very beginning of oncological management in older patients.

Clinical trial registration: This study was registered May 23, 2019 in ClinicalTrials.gov (NCT03960593).

Keywords: Aged; COVID-19; Drug-related side effects and adverse reactions; Geriatric assessment; Medical oncology; Vaccination.

Conflict of interest statement

The authors have no conflicts of interest to declare about this work.

Copyright © 2022 Elsevier Ltd. All rights reserved.

Figures

Fig. 1
Fig. 1
Study flow chart.

References

    1. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5.
    1. Aw D., Woodrow L., Ogliari G., Harwood R. Association of frailty with mortality in older inpatients with Covid-19: a cohort study. Age Ageing. 2020;49:915–922. doi: 10.1093/ageing/afaa184.
    1. Harris A.L. COVID-19 and cancer research. Br J Cancer. 2020;123:689–690. doi: 10.1038/s41416-020-0960-1.
    1. Robilotti E.V., Babady N.E., Mead P.A., Rolling T., Perez-Johnston R., Bernardes M., et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–1223. doi: 10.1038/s41591-020-0979-0.
    1. Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A., et al. Case fatality rate of Cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10:935–941. doi: 10.1158/-20-0516.
    1. HAS Stratégie de vaccination contre le Sars-Cov-2 - Recommandations préliminaires sur la stratégie de priorisation des populations à vacciner. Haute Autorité de Santé. 2020. (accessed October 19, 2021)
    1. Corti C., Crimini E., Tarantino P., Pravettoni G., Eggermont A.M.M., Delaloge S., et al. SARS-CoV-2 vaccines for cancer patients: a call to action. Eur J Cancer. 2021;148:316–327. doi: 10.1016/j.ejca.2021.01.046.
    1. Battisti N.M.L., Mislang A.R., Cooper L., O’Donovan A., Audisio R.A., Cheung K.-L., et al. Adapting care for older cancer patients during the COVID-19 pandemic: recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 working group. J Geriatr Oncol. 2020;11:1190–1198. doi: 10.1016/j.jgo.2020.07.008.
    1. ESMO ESMO Statements for vaccination against COVID-19 in patients with cancer. 2021. (accessed October 19, 2021)
    1. SoFOG Recommandations de la SoFOG en termes de vaccination contre le SARS-CoV-2 chez les patients âgés traités pour un cancer. Société Francophone d'Onco-Gériatrie. 2021.
    1. Talarico L., Chen G., Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–4631. doi: 10.1200/JCO.2004.02.175.
    1. Barrière J., Gal J., Hoch B., Cassuto O., Leysalle A., Chamorey E., et al. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol. 2021;32:673–674. doi: 10.1016/j.annonc.2021.01.066.
    1. Gustafson C.E., Kim C., Weyand C.M., Goronzy J.J. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020;145:1309–1321. doi: 10.1016/j.jaci.2020.03.017.
    1. Crooke S.N., Ovsyannikova I.G., Poland G.A., Kennedy R.B. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25. doi: 10.1186/s12979-019-0164-9.
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.
    1. Fanciullino R., Ciccolini J., Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer. 2021;124:860–861. doi: 10.1038/s41416-020-01219-3.
    1. Couderc A.-L., Boisseranc C., Rey D., Nouguerede E., Greillier L., Barlesi F., et al. Medication reconciliation associated with comprehensive geriatric assessment in older patients with Cancer: ChimioAge study. Clin Interv Aging. 2020;15:1587–1598. doi: 10.2147/CIA.S262209.
    1. Mohile S.G., Dale W., Somerfield M.R., Schonberg M.A., Boyd C.M., Burhenn P.S., et al. Practical assessment and Management of Vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36:2326–2347. doi: 10.1200/JCO.2018.78.8687.
    1. Scotte F., Bossi P., Carola E., Cudennec T., Dielenseger P., Gomes F., et al. Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. Ann Oncol. 2018;29:1718–1726. doi: 10.1093/annonc/mdy228.
    1. Son H., Kim J., Kim C., Ju J., Lee Y., Rhie S.J. Pharmacist-led interdisciplinary medication reconciliation using comprehensive medication review in gynaecological oncology patients: a prospective study. Eur J Hosp Pharm. 2018;25:21–25. doi: 10.1136/ejhpharm-2016-000937.
    1. Mekonnen A.B., McLachlan A.J., Brien J.-A.E. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41:128–144. doi: 10.1111/jcpt.12364.
    1. Gallian P., Pastorino B., Morel P., Chiaroni J., Ninove L., de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. 2020;181 doi: 10.1016/j.antiviral.2020.104880.
    1. COVIPREV . 2021. Comment évolue l’adhésion à la vaccination et aux gestes barrières contre la Covid-19 ? Résultats de la vague 25 de l’enquête CoviPrev (21–28 juin 2021)
    1. Santé Publique France Données relatives aux personnes vaccinées contre la Covid-19 (VAC-SI) - . 2021. (accessed October 20, 2021)
    1. Anderson E.J., Rouphael N.G., Widge A.T., Jackson L.A., Roberts P.C., Makhene M., et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine. 2020;383:2427–2438. doi: 10.1056/NEJMoa2028436.
    1. Monin L., Laing A.G., Muñoz-Ruiz M., McKenzie D.R., Del Molino Del Barrio I., Alaguthurai T., et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765–778. doi: 10.1016/S1470-2045(21)00213-8.
    1. Lopez Bernal J., Andrews N., Gower C., Robertson C., Stowe J., Tessier E., et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373 doi: 10.1136/bmj.n1088.
    1. Leshem E., Lopman B.A. Population immunity and vaccine protection against infection. Lancet. 2021;397:1685–1687. doi: 10.1016/S0140-6736(21)00870-9.
    1. Luo J., Rizvi H., Egger J.V., Preeshagul I.R., Wolchok J.D., Hellmann M.D. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020;10:1121–1128. doi: 10.1158/-20-0596.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する